Paper Details

  1. Home
  2. Paper Details

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Author: , AngiolilloDominick J, AntmanElliott M, BraunwaldEugene, CairnsRichard, FrelingerAndrew L, HodHanoch, JakubowskiJoseph A, McCabeCarolyn H, MichelsonAlan D, MillerDebra L, MontalescotGilles, MurphySabina A, NeumannFranz-Josef, O'DonoghueMichelle, TrenkDietmar, WiviottStephen D

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aims to evaluate the relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients.
Paper Details　
Original Abstract of the Article :
The increasing use of higher-than-approved doses of clopidogrel in clinical practice is based in part on the desire for greater levels of inhibition of platelet aggregation (IPA). Prasugrel is a new thienopyridine that is more potent than standard-dose clopidogrel in healthy subjects and patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/CIRCULATIONAHA.107.740324

データ提供：米国国立医学図書館（NLM）

Prasugrel vs. Clopidogrel: A Race for Platelet Inhibition in the Percutaneous Coronary Intervention Desert

Percutaneous coronary intervention (PCI), a procedure used to open blocked coronary arteries, is a vital treatment for heart disease. Antiplatelet medications, such as clopidogrel and prasugrel, are crucial for preventing blood clots after PCI. This research investigates the relative antiplatelet effects of prasugrel versus high-dose clopidogrel in patients undergoing PCI.

Prasugrel: A Faster and More Potent Antiplatelet Agent

The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 (PRAGUE-44) trial found that prasugrel was more potent than high-dose clopidogrel in inhibiting platelet aggregation in patients undergoing PCI. This suggests that prasugrel could provide a faster and more effective antiplatelet effect, potentially reducing the risk of blood clots after PCI. This finding could be a significant advance in the management of cardiovascular disease.

A New Path in Antiplatelet Therapy: Understanding the Implications

This research highlights the potential benefits of prasugrel as a potent antiplatelet agent in patients undergoing PCI. The study emphasizes the need for further research to determine the optimal use of prasugrel in different clinical settings. The findings suggest that prasugrel could offer a valuable alternative to high-dose clopidogrel, potentially improving patient outcomes and reducing the risk of cardiovascular events.

Dr. Camel's Conclusion

This research provides valuable insights into the relative antiplatelet effects of prasugrel and clopidogrel in patients undergoing PCI. The study highlights the potential benefits of prasugrel as a potent antiplatelet agent, suggesting that it could offer a valuable alternative to high-dose clopidogrel in certain clinical settings.

Date :
  1. Date Completed 2008-01-10
  2. Date Revised 2023-10-24
Further Info :

Pubmed ID

18056526

DOI: Digital Object Identifier

10.1161/CIRCULATIONAHA.107.740324

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.